Ingredient Guide
Myo-Inositol: Benefits, Dosage, and What the Research Says
The second-messenger molecule research has linked to hormonal balance, insulin sensitivity, and nervous system support
Written by Jessica Medson
Myo-inositol is a naturally occurring sugar alcohol that serves as a cellular second messenger in insulin, follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH) signaling pathways. It is the most clinically researched of the nine inositol stereoisomers, with a 2023 meta-analysis of 26 randomized controlled trials (1,691 participants) finding that inositol-supplemented women with PCOS were 1.79 times more likely to achieve regular menstrual cycles than those given placebo. The evidence is strongest for PCOS-related hormonal and insulin markers; benefits in other areas, including mood support and thyroid health, are supported by smaller but well-designed trials that warrant further investigation.
What Is Myo-Inositol?
Myo-inositol is a naturally occurring sugar alcohol classified within the vitamin B-complex family and sometimes called vitamin B8, though it is not a true essential vitamin because the human body can synthesize it from glucose. Of the nine possible stereoisomers of inositol, myo-inositol is the most biologically abundant and the form studied in virtually all human clinical research. It is found in high concentrations in the brain, liver, kidneys, skeletal muscle, and reproductive tissues.
Dietary sources include citrus fruits (particularly oranges and grapefruit), legumes (beans and lentils), nuts, and whole grains. However, the amounts achievable through diet alone are generally well below the gram-level doses used in clinical trials, which is why supplemental forms - available as powder or capsules - are commonly used in research and in practice.
What makes it biologically relevant
Inside cell membranes, myo-inositol serves as the structural backbone of phosphoinositides - a class of lipid second messengers that relay hormone signals from the cell surface to the cell's interior machinery. When hormones including insulin, FSH, and TSH bind to their receptors, they trigger the release of inositol-containing signaling molecules (inositol phosphoglycans, or IPGs) that activate downstream enzymes governing glucose uptake, hormone biosynthesis, and gene expression.8
Key forms and aliases
- Myo-inositol - the primary supplement form; used in the vast majority of human clinical trials
- D-chiro-inositol (DCI) - a metabolite of myo-inositol produced by an insulin-dependent enzyme; sometimes combined with myo-inositol in a 40:1 ratio that approximates physiological plasma concentrations
- Inositol - umbrella term often used interchangeably with myo-inositol in supplement labeling
- Vitamin B8 - informal designation; not recognized as an essential nutrient by the US FDA
How Does Myo-Inositol Work?
Myo-inositol's biological effects flow from its role as a second messenger - a molecular relay that amplifies and transduces signals originating at cell-surface hormone receptors. When insulin binds to the insulin receptor, one downstream consequence is the generation of inositol-containing signaling molecules (IPGs) that activate enzymes such as pyruvate dehydrogenase phosphatase, which promotes glucose oxidation. A disruption in this pathway is a recognized feature of insulin resistance.8
The insulin-resistance cycle and inositol depletion
Research has identified an important feedback loop: elevated blood glucose - as occurs in insulin resistance - competes with myo-inositol for intestinal absorption and renal reabsorption, effectively lowering intracellular inositol availability. This creates a cycle in which insulin resistance reduces the inositol signal required to restore insulin sensitivity. Supplementing myo-inositol is proposed to interrupt this cycle by replenishing the depleted second-messenger pool.8
Conversion to D-chiro-inositol
The body converts myo-inositol into DCI via an insulin-stimulated enzyme. Women with polycystic ovary syndrome (PCOS) demonstrate impaired conversion efficiency, reducing DCI availability in peripheral tissues where it is needed to complete the insulin signaling cascade. This impairment is the principal mechanistic rationale for myo-inositol supplementation in PCOS - and for the use of fixed myo-inositol:DCI ratios in some clinical protocols.
Central nervous system effects
In the brain, myo-inositol is a substrate for the phosphatidylinositol cycle, which regulates receptor sensitivity for serotonin and norepinephrine. This mechanism - the same one implicated in the action of lithium and certain antidepressants - forms the basis of research into myo-inositol for mood and anxiety support.
Hormonal Balance and PCOS Support
The most extensively studied use of myo-inositol is polycystic ovary syndrome (PCOS), a hormonal condition affecting an estimated 10-15% of reproductive-age women and characterized by irregular menstrual cycles, elevated androgens, impaired ovulation, and frequently co-occurring insulin resistance.
What the research shows
A 2017 meta-analysis of nine RCTs (247 treatment cases, 249 controls) found that myo-inositol supplementation produced statistically significant decreases in fasting insulin (SMD -1.021 µU/mL, P = 0.009) and HOMA-IR (SMD -0.585, P = 0.041). In trials lasting at least 24 weeks, sex hormone-binding globulin (SHBG) - which reduces the bioavailability of free androgens - increased significantly as well.1
A larger 2023 systematic review and meta-analysis pooling 26 RCTs with 1,691 participants found that inositol users were 1.79 times more likely to achieve regular menstrual cycles compared to placebo (95% CI: 1.13-2.85). The pooled analysis also documented reductions in free testosterone (-0.41) and total testosterone (-20.39 nmol/L), and increases in SHBG (+32.06), compared to placebo. The review concluded that inositol demonstrated non-inferiority to metformin across most metabolic outcomes while producing significantly fewer adverse events.2
A 2022 meta-analysis comparing myo-inositol directly to metformin across nine RCTs (612 patients) found that myo-inositol produced greater reductions in triglycerides (SMD -0.49, P = 0.0001) and significantly fewer side effects (RR = 0.14, P less than 0.00001).4
Where the evidence is less consistent
A separate 2022 meta-analysis of 17 RCTs (1,083 PCOS patients) did not find statistically significant improvement in BMI, fasting glucose, fasting insulin, HOMA-IR, total testosterone, SHBG, LH, FSH, or estradiol after myo-inositol treatment.5 This discrepancy across meta-analyses likely reflects heterogeneity in PCOS phenotypes, dosing regimens, study durations, and comparator groups. The preponderance of data supports modest-to-moderate effects on insulin markers and menstrual regularity; effects on androgen levels and body composition are less reproducible.
Fertility and IVF outcomes
A 2022 double-blind RCT of 60 women undergoing IVF or ICSI found that those who received 2,000 mg myo-inositol plus 200 mcg folic acid twice daily for two months retrieved significantly more total oocytes (9.67 vs 6.83, p = 0.04) and mature MII oocytes (7.53 vs 5.43, p = 0.04). Clinical pregnancy rate was 56.66% in the myo-inositol group versus 23.33% in the folic acid-only control (p = 0.04).11 These results are encouraging, though this was a single relatively small trial and replication in larger studies is needed before broad conclusions can be drawn.
Glucose Metabolism and Insulin Sensitivity
Beyond PCOS, myo-inositol has been studied for its effects on glucose regulation in broader metabolic contexts - most notably gestational diabetes mellitus (GDM) and general metabolic syndrome.
What the research shows
A 2024 meta-analysis of four RCTs involving 317 patients with gestational diabetes found that myo-inositol supplementation significantly reduced both the requirement for insulin treatment (OR = 0.24; 95% CI 0.11-0.52) and insulin resistance measured by HOMA-IR (SMD = -1.18; 95% CI -1.50 to -0.87) compared to routine care alone. No significant differences in birth weight, cesarean delivery rates, or NICU admissions were observed, suggesting a favorable fetal safety profile.3
The mechanistic basis for these findings aligns with the second-messenger research: myo-inositol and its metabolite DCI improve the efficiency of insulin's intracellular signaling cascade, an effect researchers describe as occurring independently of changes in body weight.8
Taken together, the insulin-related evidence - drawn from PCOS populations, women with gestational diabetes, and mechanistic reviews - consistently points toward a role in supporting healthy insulin signaling. The strongest effects appear in settings where insulin resistance is already present. Evidence for metabolic benefits in otherwise healthy, insulin-sensitive adults is limited.
Mood and Nervous System Support
Inositol has a longer history in psychiatry research than many people realize. Because the phosphatidylinositol signaling cycle is implicated in the mechanism of action of lithium and several classes of antidepressants, early researchers investigated whether high-dose inositol supplementation might augment this pathway in anxiety and mood conditions.
What the research shows
A double-blind, placebo-controlled crossover trial in 21 patients with panic disorder found that 12 g/day of inositol over four weeks significantly reduced both the frequency and severity of panic attacks, and the severity of agoraphobia, compared to placebo. Side effects were described as minimal.6
A follow-up crossover trial directly compared inositol (up to 18 g/day) against the SSRI fluvoxamine (up to 150 mg/day) in 20 patients with panic disorder. Inositol reduced panic attacks by 4.0 per week versus 2.4 with fluvoxamine (p = 0.049). Inositol also produced significantly less nausea (p = 0.02) and tiredness (p = 0.01).9
Important context for interpreting this evidence
These are small early-phase trials published in the 1990s and early 2000s. The doses studied (12-18 g/day) are substantially higher than the 2-4 g/day doses used for metabolic and hormonal applications and far above typical supplement servings. This body of research does not establish that myo-inositol replaces evaluated clinical treatments for anxiety or panic disorder, and larger confirmatory trials have not followed. This area remains a promising but preliminary line of inquiry.
Thyroid Health and Autoimmune Thyroiditis
Myo-inositol plays a structural role in TSH receptor signaling, where it serves as a second messenger that facilitates the synthesis of thyroid hormones. Depletion of intracellular inositol has been proposed as a factor that may impair normal thyroid hormone production, which has prompted research in individuals with autoimmune thyroid conditions.10
What the research shows
An RCT of 168 patients with Hashimoto's thyroiditis and mildly elevated TSH (3-6 µIU/mL) compared combined myo-inositol plus selenomethionine supplementation against selenomethionine alone over six months. The combination group showed significantly greater reductions in TSH, anti-TPO antibodies (TPOAb), and anti-thyroglobulin antibodies (TgAb), along with a meaningful increase in free serum T4, compared to selenium alone.7
A narrative review of this mechanism concluded that myo-inositol is an essential precursor for the hydrogen peroxide production required for thyroid hormone synthesis, and that TSH-driven inositol depletion may contribute to hypothyroid states in susceptible individuals.10
Limitation: Published trials have consistently studied myo-inositol in combination with selenium, not myo-inositol alone. It is not currently possible to separate the individual contributions of each component. This remains a developing evidence base.
Safety, Side Effects, and Interactions
General safety profile: Myo-inositol has a well-established tolerability record across human clinical trials. At doses used for metabolic and hormonal applications (2-4 g/day), adverse events are uncommon and mild. The 2023 meta-analysis of 26 PCOS RCTs explicitly reported non-inferiority to metformin with significantly fewer adverse events.2 Myo-inositol is recognized as Generally Recognized As Safe (GRAS) by the US FDA for food use, and no tolerable upper intake level has been established.
Common side effects
- Gastrointestinal symptoms - nausea, bloating, flatulence, or loose stools - are the most frequently reported effects and occur primarily at higher doses (above 4 g/day). These are generally dose-dependent and transient.
- At the very high doses used in psychiatric research (12-18 g/day), GI discomfort was the principal complaint, though most participants in those trials completed the study.
Populations requiring caution or medical supervision
- Pregnancy: Myo-inositol at 4 g/day has been specifically studied in pregnant women in RCTs and appears well tolerated. However, any supplement use during pregnancy should be discussed with a qualified healthcare provider before starting.
- Breastfeeding: Adequate safety data in lactating women is limited. Consult a healthcare provider before use.
- Bipolar disorder: Because inositol modulates serotonergic and noradrenergic signaling, there is a theoretical concern regarding mood destabilization at high doses in individuals with bipolar disorder. High-dose inositol supplementation in this population should only be pursued under physician supervision.
- Diabetes medications: Myo-inositol may support insulin sensitivity and lower fasting glucose. Combining it with insulin, metformin, sulfonylureas, GLP-1 receptor agonists, or other glucose-lowering agents could theoretically increase hypoglycemia risk. Blood glucose monitoring is advisable when initiating supplementation alongside these therapies.
- Lithium therapy: Preclinical evidence suggests inositol may partially counteract aspects of lithium's mechanism of action. Anyone taking lithium should consult their prescribing clinician before supplementing with inositol.
This article does not constitute medical advice. Always consult a qualified healthcare professional before adding any new supplement to your routine, particularly if you have an existing medical condition or take prescription medications.
Myo-Inositol Dosage Guide (Based on Clinical Trial Protocols)
Doses below reflect ranges used in published human clinical trials. They are not personalized medical recommendations. Optimal dosing depends on individual health status and goals - consult a healthcare provider.
| Goal | Typical Dose | Timing | Notes |
|---|---|---|---|
| PCOS - hormonal and metabolic support | 2,000-4,000 mg/day | Divided into two doses with meals (morning and evening) | Most trials used 2,000 mg twice daily; often combined with 200 mcg folic acid; benefit on menstrual regularity most apparent after 12-24 weeks |
| Gestational diabetes management (under medical supervision) | 4,000 mg/day | 2,000 mg twice daily with food | Used with 400 mcg folic acid in most protocols; should not be self-initiated in pregnancy without physician oversight |
| IVF / oocyte quality support | 4,000 mg/day | 2,000 mg twice daily for at least 8 weeks before egg retrieval | Based on a single double-blind RCT (PMID 36313255); evidence is promising but preliminary |
| General insulin and metabolic support | 2,000-4,000 mg/day | With meals, divided | Less evidence available in non-PCOS populations; individual results will vary |
| Anxiety/panic support (investigational; not a standard recommendation) | 12,000-18,000 mg/day | Divided across 3 doses daily | Doses from 1990s small crossover trials only; substantially higher than metabolic doses; not appropriate without physician guidance; do not substitute for evaluated clinical care |
The 40:1 myo-inositol to D-chiro-inositol ratio (e.g., 2,000 mg MI + 50 mg DCI) is used in some commercial formulations based on physiological plasma ratios, but evidence comparing fixed-ratio combinations to myo-inositol alone remains limited.
Myo-Inositol: What the Evidence Shows at a Glance
A summary of human clinical trial evidence by outcome area. Tier A = human RCT or meta-analysis; Tier B = human observational or narrative review; Tier C = animal or cell data only.
| Outcome / Application | Population studied | What studies show | Evidence tier |
|---|---|---|---|
| Menstrual cycle regularity (PCOS) | Women with PCOS (26 RCTs, 1,691 participants) | 1.79x higher likelihood of regular cycles vs placebo; significant reduction in cycle length irregularity | Tier A |
| Insulin resistance / HOMA-IR (PCOS) | Women with PCOS (9-26 RCTs across meta-analyses) | Significant reductions in fasting insulin and HOMA-IR in most (not all) meta-analyses; results vary by phenotype and study duration | Tier A |
| Free and total testosterone (PCOS) | Women with PCOS | Reductions reported in some meta-analyses; not statistically significant in others; inconsistent across studies | Tier A |
| SHBG levels (PCOS) | Women with PCOS (trials of at least 24 weeks) | Significant increases in SHBG vs placebo in longer trials; may reduce free androgen bioavailability | Tier A |
| Insulin need in gestational diabetes | Pregnant women with GDM (4 RCTs, 317 patients) | Significant reduction in insulin requirement (OR 0.24) and HOMA-IR (SMD -1.18) | Tier A |
| Oocyte count and IVF pregnancy rate | Infertile women undergoing IVF/ICSI (1 double-blind RCT) | More oocytes retrieved; clinical pregnancy rate 56.66% vs 23.33% in control; replication needed | Tier A |
| Panic attack frequency | Adults with panic disorder (2 small crossover RCTs) | Reduced frequency and severity vs placebo; comparable to fluvoxamine in one head-to-head trial; very small sample sizes | Tier A |
| TSH and thyroid antibodies (Hashimoto's) | Patients with Hashimoto's + subclinical hypothyroidism (1 RCT) | Combined myo-inositol + selenium reduced TSH, TPOAb, TgAb vs selenium alone; cannot isolate inositol-only effect | Tier A |
| Body weight / BMI (PCOS) | Women with PCOS | No significant effect on BMI across most meta-analyses | Tier A |
| Triglycerides (PCOS vs metformin) | Women with PCOS (9 RCTs vs metformin) | Superior triglyceride reduction vs metformin (SMD -0.49); fewer adverse events (RR 0.14) | Tier A |
Tier A evidence from human RCTs and meta-analyses is the most clinically relevant but does not guarantee the same effect in any individual. Study populations and protocols vary widely.
Frequently Asked Questions
What is myo-inositol good for?
Myo-inositol is most studied for supporting hormonal and metabolic balance in women with PCOS, where clinical trials consistently show improvements in menstrual regularity and insulin sensitivity markers. Research also covers gestational diabetes management, egg quality for IVF, thyroid support in Hashimoto's patients, and anxiety-related outcomes - though evidence strength varies across these applications.
How much myo-inositol should I take per day?
Clinical trials for PCOS and metabolic applications typically use 2,000-4,000 mg per day, split into two doses with meals. Psychiatric research used much higher doses (12,000-18,000 mg/day), which are not standard supplement doses and should not be attempted without physician guidance. The appropriate dose depends on your health goal.
Does myo-inositol actually work for PCOS?
The evidence is cautiously positive but mixed. A 2023 meta-analysis of 26 RCTs (1,691 women) found inositol users 1.79 times more likely to achieve regular menstrual cycles than placebo, with meaningful improvements in insulin resistance markers and testosterone levels. However, a separate 2022 meta-analysis of 17 RCTs did not find significant effects on BMI, fasting glucose, or total testosterone, illustrating that results depend on PCOS phenotype and study design.
How long does myo-inositol take to work?
Clinical trials reporting significant effects on menstrual regularity and SHBG typically ran for 12-24 weeks. Insulin markers (fasting insulin, HOMA-IR) sometimes improved in shorter trials of 8-12 weeks. Most researchers suggest evaluating response after at least three menstrual cycles, or roughly 3 months of consistent use at an adequate dose.
What is the difference between myo-inositol and D-chiro-inositol?
Myo-inositol is the most abundant form in the body and functions as the primary cell-signaling precursor. D-chiro-inositol (DCI) is a metabolite of myo-inositol produced by an insulin-dependent enzyme. Women with PCOS appear to convert myo-inositol to DCI less efficiently. Some supplements combine both in a 40:1 ratio that approximates normal physiological plasma levels, though evidence comparing combination products to myo-inositol alone is still limited.
Is myo-inositol safe?
Yes, at commonly used doses (2-4 g/day), myo-inositol has a well-established safety record across multiple large-scale RCTs and meta-analyses. It is recognized as GRAS (Generally Recognized As Safe) by the US FDA. The main side effects are mild gastrointestinal symptoms (nausea, bloating) that tend to occur at higher doses. Those taking glucose-lowering medications, lithium, or who are pregnant should consult a healthcare provider before use.
Can myo-inositol improve fertility or IVF outcomes?
One double-blind RCT in 60 women undergoing IVF found that 4,000 mg/day of myo-inositol plus folic acid for two months significantly increased oocyte count and mature egg yield, and nearly doubled the clinical pregnancy rate (56.66% vs 23.33%) compared to folic acid alone. These results are promising, but this is a single small trial and should not be interpreted as definitive without larger confirmatory studies.
Does myo-inositol help with weight loss?
The current evidence does not support myo-inositol as a weight loss supplement. Across most PCOS meta-analyses, including a pooled analysis of 26 RCTs, no statistically significant reduction in BMI was observed with myo-inositol versus placebo or metformin. Any benefits observed in metabolic markers appear largely independent of body weight change.
Can I take myo-inositol while pregnant?
Myo-inositol at 4,000 mg/day has been studied specifically in pregnant women in RCTs examining gestational diabetes, with a favorable safety profile for both mother and infant. However, supplement use during pregnancy carries individual variability, and any supplementation plan during pregnancy must be discussed with an obstetrician or qualified healthcare provider before starting.
Does myo-inositol help with anxiety?
Two small double-blind crossover RCTs found that high-dose inositol (12-18 g/day) reduced panic attack frequency and severity, with one trial showing results comparable to the SSRI fluvoxamine. However, these trials involved just 20-21 participants and used doses far above standard supplement servings. This evidence is preliminary and does not position myo-inositol as a replacement for clinically evaluated anxiety treatments.
Shop Myo-Inositol
HealthFare Myo-Inositol supplements
Scientific References
- 1.Unfer V, Facchinetti F, Orru B, Giordani B, Nestler J Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocrine Connections. 2017. PubMed: 29042448Clinical (RCT / meta-analysis)
- 2.Greff D, Juhasz AE, Vancsa S, Varadi A, Sipos Z, Szinte J, Park S, Hegyi P, Nyirady P, Acs N, Varbiro S, Horvath EM Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology. 2023. PubMed: 36703143Clinical (RCT / meta-analysis)
- 3.Chen H, Xiong J, Li Z, Chen Y, Zhang M, Chen D, Liu B Influence of myo-inositol on metabolic status for gestational diabetes: a meta-analysis of randomized controlled trials. Journal of Maternal-Fetal and Neonatal Medicine. 2024. PubMed: 39115013Clinical (RCT / meta-analysis)
- 4.Zhang JQ, Xing C, He B Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials. European Review for Medical and Pharmacological Sciences. 2022. PubMed: 35363325Clinical (RCT / meta-analysis)
- 5.Jethaliya H, Gajjar N, Patel V, Deshpande S, Patel R Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial. Reproductive Sciences. 2022. PubMed: 35477841Clinical (RCT / meta-analysis)
- 6.Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. American Journal of Psychiatry. 1995. PubMed: 7793450Clinical (RCT / meta-analysis)
- 7.Nordio M, Basciani S Myo-inositol plus selenium supplementation restores euthyroid state in Hashimoto's patients with subclinical hypothyroidism. European Review for Medical and Pharmacological Sciences. 2017. PubMed: 28724185Clinical (RCT / meta-analysis)
- 8.Bevilacqua A, Bizzarri M Inositols in Insulin Signaling and Glucose Metabolism. International Journal of Endocrinology. 2018. PubMed: 30595691Human observational
- 9.Palatnik A, Frolov K, Fux M, Benjamin J Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. Journal of Clinical Psychopharmacology. 2001. PubMed: 11386498Clinical (RCT / meta-analysis)
- 10.Fallahi P, Ferrari SM, Elia G, Ragusa F, Paparo SR, Caruso C, Guglielmi G, Antonelli A Myo-inositol in autoimmune thyroiditis, and hypothyroidism. Reviews in Endocrine and Metabolic Disorders. 2018. PubMed: 30506520Human observational
- 11.Seyedoshohadaei F, Abbasi S, Rezaie M, Allahvaisi A, Rezaie MJ, Soufizadeh N, Rahmani K Myo-inositol effect on pregnancy outcomes in infertile women undergoing in vitro fertilization/intracytoplasmic sperm injection: A double-blind RCT. International Journal of Reproductive Biomedicine. 2022. PubMed: 36313255Clinical (RCT / meta-analysis)